EF Hutton Maintains Buy on Apexigen, Lowers Price Target to $5
$APGN
Biotechnology: Pharmaceutical Preparations
Health Care
EF Hutton analyst Tony Butler maintains Apexigen (NASDAQ:APGN) with a Buy and lowers the price target from $8 to $5.
Save time and jump to the most important pieces.
Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. ("Pyx
-Patients with liposarcoma (LPS) demonstrated prolonged median PFS (mPFS) relative to historical controls treated with standard of care of doxorubicin- -Encouraging PFS data from the ongoing investigator sponsored trial in collaboration with Columbia University supports expansion of the LPS cohort to inform a potential phase 3 registration-enabling trial- -Apexigen to host investor call with sarcoma expert and principal investigator, Gary Schwartz, M.D. at Columbia University, today, November 14, at 8:00 a.m. ET- SAN CARLOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeu
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
15-12G - Apexigen, Inc. (0001814140) (Filer)
S-8 POS - Apexigen, Inc. (0001814140) (Filer)
8-K - Apexigen, Inc. (0001814140) (Filer)
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of APGN and Pyxis Oncology, Inc. Under the terms of the proposed merger, APGN shareholders will receive 0.1725 shares of Pyxis Oncology, Inc. common stock for each share of APGN common stock owned. Following the merger, pre-merger Apexigen shareholders are expected to own approximately 10% of the outstanding equity of the combined company. If you are an APGN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz
- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) - - DDLPS expansion cohort enrolling to inform a potential Phase 3 registration trial - SAN CARLOS, Calif., June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab (sotiga), Ap
Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. ("Pyx
SC 13G/A - Apexigen, Inc. (0001814140) (Subject)
SC 13G - Apexigen, Inc. (0001814140) (Subject)
SC 13G/A - Apexigen, Inc. (0001814140) (Subject)
EF Hutton analyst Tony Butler reiterates Apexigen (NASDAQ:APGN) with a Hold and maintains $0.64 price target.
Gainers HeartBeam (NASDAQ:BEAT) stock rose 20.1% to $2.42 during Thursday's pre-market session. The company's market cap stands at $62.6 million. Prelude Therapeutics (NASDAQ:PRLD) shares increased by 11.43% to $5.75. The market value of their outstanding shares is at $275.7 million. Benitec Biopharma (NASDAQ:BNTC) shares rose 10.36% to $0.23. The market value of their outstanding shares is at $6.4 million. Predictive Oncology (NASDAQ:POAI) shares moved upwards by 10.19% to $3.46. The market value of their outstanding shares is at $13.8 million. Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 9.71% to $5.42. The company's market cap stands at $32.9 million. The company's, Q1 earnings
Pyxis Oncology Inc (NASDAQ:PYXS) agreed to acquire Apexigen Inc (NASDAQ:APGN) in an all-stock transaction for an implied value of $0.64 per Apexigen share. Apexigen went public in a blank-check deal just last summer. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock for a total enterprise value of approximately $16 million. In February, Apexigen announced evaluating alternatives and reduced its workforce by 55%. "This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation by adding humanized antibody generation to our Flexible Antibody Conjugation Technology (FACT) ADC toolkit acquired from Pfize